{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T04:52:51Z","timestamp":1770267171925,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.rmed.2019.10.005","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T18:10:31Z","timestamp":1570471831000},"page":"42-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers"],"prefix":"10.1016","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5949-248X","authenticated-orcid":false,"given":"Kyung-Wook","family":"Jo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju Sang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyouk-Soo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yea Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Jee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-816X","authenticated-orcid":false,"given":"Tae Sun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"48","key":"10.1016\/j.rmed.2019.10.005_bib1","first-page":"1650","article-title":"Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","author":"Centers for Disease C","year":"2011","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"23","key":"10.1016\/j.rmed.2019.10.005_bib2","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Team TBTCPTS. Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2019.10.005_bib3","series-title":"Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management: Annex 3: Values and Preferences for the Management of Latent Tuberculosis Infection: Survey of Populations Affected by the Recommendations","author":"World Health Organization","year":"2018"},{"issue":"1","key":"10.1016\/j.rmed.2019.10.005_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.rmed.2019.10.005_bib5","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.rmed.2019.10.005_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"10","key":"10.1016\/j.rmed.2019.10.005_bib7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/resp.13346","article-title":"Latent tuberculosis infection: opportunities and challenges","volume":"23","author":"Chee","year":"2018","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.rmed.2019.10.005_bib8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.rmed.2019.10.005_bib9","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.5588\/ijtld.13.0423","article-title":"Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States","volume":"17","author":"Shepardson","year":"2013","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"4","key":"10.1016\/j.rmed.2019.10.005_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.rmed.2019.10.005_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01470-2018","article-title":"Team L-Ns. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study","volume":"52","author":"Gao","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.rmed.2019.10.005_bib12","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3201\/eid2111.141894","article-title":"Achievements in and challenges of tuberculosis Control in South Korea","volume":"21","author":"Kim","year":"2015","journal-title":"Emerg. Infect. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2019.10.005_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4046\/trd.2017.0052","article-title":"Treatment of latent tuberculosis infection and its clinical efficacy","volume":"81","author":"Kim","year":"2018","journal-title":"Tuberc. Respir. Dis."},{"issue":"2","key":"10.1016\/j.rmed.2019.10.005_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4046\/trd.2015.78.2.56","article-title":"Diagnosis and treatment of latent tuberculosis infection","volume":"78","author":"Lee","year":"2015","journal-title":"Tuberc. Respir. Dis."},{"issue":"7","key":"10.1016\/j.rmed.2019.10.005_bib15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3346\/jkms.2012.27.7.761","article-title":"Positive tuberculin skin test or interferon-gamma release assay in patients with radiographic lesion suggesting old healed tuberculosis","volume":"27","author":"Jeong","year":"2012","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.rmed.2019.10.005_bib16","series-title":"Korean Guidelines for Tuberculosis","author":"Joint Committee for the Revision of Korean Guidelines for Tuberculosis and Korea Centers for Disease Control and Prevention","year":"2017"},{"issue":"3","key":"10.1016\/j.rmed.2019.10.005_bib17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.5588\/ijtld.14.0554","article-title":"Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy","volume":"19","author":"Park","year":"2015","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.rmed.2019.10.005_bib18","author":"U.S. Department of Health and Human Services"},{"issue":"9","key":"10.1016\/j.rmed.2019.10.005_bib19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI","volume":"19","author":"Bliven-Sizemore","year":"2015","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"1","key":"10.1016\/j.rmed.2019.10.005_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cid\/civ766","article-title":"Treatment for tuberculosis infection with 3 Months of isoniazid and rifapentine in New York city health department clinics","volume":"62","author":"Stennis","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.rmed.2019.10.005_bib21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.7326\/M17-2639","article-title":"Tailoring treatment of latent tuberculosis to the needs of patients and families","volume":"167","author":"Getahun","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"10","key":"10.1016\/j.rmed.2019.10.005_bib22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.rmed.2019.10.005_bib23","series-title":"Global Tuberculosis Report 2018","author":"World Health Organization","year":"2018"},{"issue":"3","key":"10.1016\/j.rmed.2019.10.005_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0041-3879(74)90046-4","article-title":"A controlled clinical trial of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy in Hong Kong: second report:-the results at 12 months","volume":"55","year":"1974","journal-title":"Tubercle"},{"issue":"Suppl 3","key":"10.1016\/j.rmed.2019.10.005_bib25","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1093\/clinids\/5.Supplement_3.S440","article-title":"Adverse effects of rifampin","volume":"5","author":"Grosset","year":"1983","journal-title":"Rev. Infect. Dis."},{"issue":"2","key":"10.1016\/j.rmed.2019.10.005_bib26","first-page":"87","article-title":"Adverse reactions during rifampicin treatment","volume":"53","author":"Riska","year":"1972","journal-title":"Scand. J. Respir. Dis."},{"issue":"2","key":"10.1016\/j.rmed.2019.10.005_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/jac\/3.2.115","article-title":"Adverse reactions to rifampicin in antituberculosis regimens","volume":"3","author":"Girling","year":"1977","journal-title":"J. Antimicrob. Chemother."},{"issue":"31","key":"10.1016\/j.rmed.2019.10.005_bib28","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.rmed.2019.10.005_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02396-2018","article-title":"Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly","volume":"53","author":"Chan","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.rmed.2019.10.005_bib30","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1164\/rccm.200201-047OC","article-title":"Tuberculosis Trials Consortium CfDC, Prevention AG. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment","volume":"165","author":"Bock","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2019.10.005_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1164\/arrd.1983.128.3.419","article-title":"Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis","volume":"128","author":"Dutt","year":"1983","journal-title":"Am. Rev. Respir. Dis."},{"issue":"5803","key":"10.1016\/j.rmed.2019.10.005_bib32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/bmj.1.5803.765","article-title":"Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong","volume":"1","author":"Aquinas","year":"1972","journal-title":"Br. Med. J."},{"issue":"11","key":"10.1016\/j.rmed.2019.10.005_bib33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119303075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119303075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:57:55Z","timestamp":1760615875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611119303075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":33,"alternative-id":["S0954611119303075"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2019.10.005","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2019.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}